Chester County News and Community Website
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) more than doubled second-quarter research spending as its pivotal Phase 3 Alzheimer’s disease trial reached full enrollment at 850 patients, positioning the …
Annovis R&D Costs Surge as Alzheimer’s Trial Reaches Full Enrollment Read More
KING OF PRUSSIA, PA — Nocopi Technologies, Inc. (OTCQB: NNUP) posted a 167% increase in second-quarter revenue to $960,000 as its Polymeric Group acquisition added sales and ink shipments increased, …
Nocopi Revenue Jumps 167% as Acquisition Lifts Sales Read More
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) is targeting a second-half 2027 Biologics License Application for rese-cel in myositis while preparing another registrational study in systemic sclerosis, advancing its …
Cabaletta Targets 2027 BLA as Cell Therapy Trials Advance Read More
EXTON, PA — Omega Flex, Inc. (NASDAQ: OFLX) reported a 38.5% drop in first-half net income as weaker housing activity reduced sales volumes and higher raw material, tariff and product-launch …
Omega Flex Profit Falls 39% as Housing Weakness Hits Sales Read More
NORTH WALES, PA — Toppoint Holdings Inc. (NYSE American: TOPP) narrowed its second-quarter net loss by 80% as revenue rose 17% and a shift toward higher-value import and metal freight …
Toppoint Narrows Loss as Import, Metal Mix Lifts Margins Read More
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (NASDAQ: AVBP) is approaching a pivotal Phase 3 readout for its lead lung cancer drug while advancing two antibody-drug conjugates into later stages …
ArriVent Nears Pivotal Lung Cancer Data With $373 Million Cash Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (NASDAQ: APRE) is expanding its Phase 1 trial of experimental cancer drug APR-1051 after reporting early signs of antitumor activity, using proceeds from a …
Aprea Expands Cancer Trial as APR-1051 Shows Early Activity Read More
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) is targeting a fourth-quarter 2026 regulatory filing for its experimental type 1 diabetes cell therapy after reaching general alignment with the U.S. …
Century Targets FDA Filing for Diabetes Cell Therapy Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) plans to return up to approximately $230 million to shareholders after receiving $178.4 million from its patent settlement with Moderna, shifting capital …
Arbutus Plans $230 Million Share Buyback After Moderna Deal Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) ended the second quarter with $661.4 million in cash, cash equivalents and investments after raising equity and debt capital and spending $200 …
Mineralys Builds $661 Million War Chest Ahead of FDA Decision Read More